NIH-funded research R03 grant

Investigating how Group B Streptococcus interacts with its host

Official title: A Group B Streptococcus ordered CRISPR interference library to investigate host-pathogen interactions

Funded at University of Texas Dallas · NIH-11302596 · Data updated 2026-11-12

This study is looking at how a common germ called Group B Streptococcus (GBS) behaves in our bodies, especially in newborns and people with weakened immune systems, to find new ways to prevent infections, like possibly creating vaccines.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionUniversity of Texas Dallas
NIH-funded
Lab location1 site (Richardson, United States)
Project startJune 10, 2024
Project endApril 30, 2026
Funding year2025
Award (this year)$78,000
NIH project number7R03AI185593-02
Project IDNIH-11302596 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are newborns, pregnant women, and immunocompromised individuals who are at higher risk for GBS infections.

Less likely to help

Patients who are healthy adults without risk factors for GBS infections may not receive direct benefits from this research.

What this research studies

This research focuses on understanding how Group B Streptococcus (GBS), a common bacterium that can cause serious infections, interacts with the human body. Using advanced CRISPR interference technology, researchers will create a library that allows them to selectively turn down the activity of specific genes in GBS. This approach aims to uncover the mechanisms behind GBS colonization and its potential to cause disease, particularly in vulnerable populations like newborns and immunocompromised individuals. The findings could lead to new strategies for preventing GBS infections, including the development of vaccines.

Why it matters

Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for infections caused by Group B Streptococcus.

How similar studies have gone: Other research using CRISPR technology has shown promise in understanding bacterial pathogenesis, indicating that this approach could yield valuable insights.

Where this research is happening

  • University of Texas Dallas
    Richardson, United States
    Active

Researchers

  • Principal investigator: Kim, Brandon Jonathan — University of Texas Dallas
  • Study coordinator: Kim, Brandon Jonathan

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.